Positron emission tomography: Current status and future challenges

Internal Medicine Journal

Volumn 40, Issue 1, 2010, Pages 19-29

  Lin, M ^a   Shon, I Ho ^a   Lin, P ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cancer; FDG; Oncology; Positron emission tomography

Indexed keywords

3' FLUOROTHYMIDINE F 18; ANTINEOPLASTIC AGENT; CARBON 11; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE; FLUORODEOXYGLUCOSE F 18; FLUOROMISONODAZOLE F 18; GALLIUM 68; IMATINIB; IODINE 131; METHIONINE C 11; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; THYROGLOBULIN; TRACER; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VINCRISTINE; YTTRIUM 90;

BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; ENDOSCOPIC ECHOGRAPHY; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; GLIOMA; HEAD AND NECK CANCER; HODGKIN DISEASE; HUMAN; INTRACTABLE EPILEPSY; LAPAROTOMY; LARGE CELL LYMPHOMA; LIVER METASTASIS; LUNG NODULE; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LYMPHOMA; MELANOMA; METASTASECTOMY; METASTASIS; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SARCOMA; SCINTIGRAPHY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY; TREATMENT PLANNING; TREATMENT RESPONSE;

FORECASTING; GLUCOSE-6-PHOSPHATE; HUMANS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY;

EID: 76749118090     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2009.02072.x     Document Type: Review

References (61)

1. Scott AM. Current status of positron emission tomography in oncology. Intern Med J 2001 31 : 27 36.
2. Scott A, Rowe C, Allman K, Lenzo N, Hicks R, Stuckey J et al. Australian prospective multi-centre PET data collection project - Impact of FDG PET in oncology, epilepsy and cardiac patients. J Nucl Med 2007 48 (Suppl 2 185 abstract).
3. Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L et al. Impact of Positron Emission Tomography/Computed Tomography and Positron Emission Tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 2008 26 : 2155 2161.
4. Czernin J, Allen-Auerbach M, Schelbert H. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med 2007 48 : 78S 88S.
5. Mawlawi O, Townsend DW. Multimodality imaging: an update on PET/CT technology. Eur J Nucl Med Mol Imaging 2009 36 (Suppl 1 S15 29.
6. Fletcher JW, Kymes SM, Gould M, Alazraki N, Coleman RE, Lowe VJ et al. A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med 2008 49 : 179 185.
7. Hashimoto Y, Tsujikawa T, Kondo C, Maki M, Momose M, Nagai A et al. Accuracy of PET for diagnosis of solid pulmonary lesions with 18F-FDG uptake below the standardized uptake value of 2.5. J Nucl Med 2000 47 : 426 431.
8. Fisher RE. PET for the evaluation of solitary pulmonary nodules. J Nucl Med 2009 50 : 326.
9. Lin M, Darwish BS, Chu J. Neurosyphilitic gumma on F18-2-fluoro-2-deoxy- D-glucose (FDG) positron emission tomography: An old disease investigated with a new technology. J Clin Neurosci 2009 16 : 410 412.
10. Chen W. Clinical applications of PET in brain tumors. J Nucl Med 2007 48 : 1468 1481.
11. Even-Sapir E, Lerman H, Gutman M, Lievshitz G, Zuriel L, Polliack A et al. The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT. Eur J Nucl Med Mol Imaging 2006 33 : 541 552.
12. Hillman BJ. Screening for cancer with high technology imaging tests. J Clin Oncol 2009 27 : 1740 1741.
13. Nishizawa S, Kojima S, Teramukai S, Inubushi M, Kodama H, Maeda Y et al. Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]Fluorodeoxyglucose Positron Emission Tomography in a healthy population: a preliminary report. J Clin Oncol 2009 27 : 1767 1773.
14. Yap KK, Yap KS, Byrne AJ, Berlangieri SU, Poon A, Mitchell P et al. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2005 32 : 1033 1040.
15. The Cancer Council of Australia. Clinical Practice Guidelines for the Prevention, Diagnosis and Management of Lung Cancer. National Health and Medical Research Council 2004.
16. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small cell lung cancer - a meta-analysis. Ann Intern Med 2003 139 : 879 892.
17. Pieterman RM, van Putten JWG, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000 343 : 254 261.
18. Van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: The PLUS multicentre randomized trial. Lancet 2002 359 : 1388 1393.
19. Hoekstra CJ, Stroobants SG, Hoekstra OS, Vansteenkiste J, Biesma B, Schramel FJHM et al. The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small-cell lung cancer for combined modality treatment. Lung Cancer 2003 39 : 151 157.
20. Schiepers C, Filmont JE, Czernin J. PET for staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging 2003 30 (Suppl 1 S82 8.
21. Scott AM, Gunawardana DH, Wong J, Kirkwood I, Hicks RJ, Ho Shon I et al. Positron emission tomography changes management, improves prognostic stratification and is superior to gallium scintigraphy in patients with low-grade lymphoma: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging 2009 36 : 347 353.
22. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 2005 46 : 958 963.
23. Schaefer NG, Strobel K, Christian Taverna C, Hany TF. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging 2007 34 : 60.
24. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007 92 : 50 5.
25. van Vliet EPM, Heijenbrok-Kal MH, Hunink MGM, Kuipers EJ, Siersema PD. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer 2008 98 : 547 557.
26. Chatterton BE, Ho Shon I, Baldey A, Lenzo N, Patrikeos A, Kelley B et al. Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging 2009 36 : 354 361.
27. Kim SK, Kang KW, Lee JS, Kim HK, Chang HJ, Choi JY et al. Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer. Eur J Nucl Med Mol Imaging 2006 33 : 148 155.
28. Llamas-Elvira JM, Rodríguez-Fernández A, Gutiérrez-Sáinz J, Gomez-Rio M, Bellon-Guardia M, Ramos-Font C et al. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging 2007 34 : 859 867.
29. Davey K, Heriot AG, Mackay J, Drummond E, Hogg A, Ngan S et al. The impact of 18-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography on the staging and management of primary rectal cancer. Dis Colon Rectum 2008 51 : 997 1003.
30. Scott AM, Gunawardana DH, Bartholomeusz D, Ramshaw JE, Lin P. PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a Multicenter Prospective Study. J Nucl Med 2008 49 : 1593 1600.
31. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008 49 : 480 508.
32. Lai CH, Yen TC, Chang TC. Positron emission tomography imaging for gynaecologic malignancy. Curr Opin Obstet Gynecol 2007 19 : 37 41.
33. Hodgson NC, Gulenchyn KY. Is there a role for Positron Emission Tomography in breast cancer staging? J Clin Oncol 2008 26 : 712 720.
34. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009 45 : 228 247.
35. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007 25 : 571 578.
36. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma:a systematic review. Haematologica 2006 91 : 522 529.
37. Kobe C, Dietlein M, Franklin J, Markova J, Lohri A, Amthauer H et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008 112 : 3989 3994.
38. Mikhaeel NG, Hutchings M, Fields PA, O'Doherty MJ, Timothy AR. FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005 16 : 1514 1523.
39. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Grooot T et al. Early restaging positron emission tomography with (18)F- fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol 2002 13 : 1356 1363.
40. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007 25 : 3746 3752.
41. Hutchings M, Barrington SF. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2009 50 : 21S 30S.
42. Song SY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced resectable esophageal cancer. Int J Radiat Oncol Biol Phys 2005 63 (4 1053 1059.
43. Melton GB, Lavely WC, Jacene HA, Schulick RD, Choti MA, Wahl RL et al. Efficacy of preoperative combined 18-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography for assessing primary rectal cancer response to neoadjuvant therapy. J Gastrointest Surg 2007 11 : 961 969.
44. Cascini GL, Avallone A, Delrio P, Guida C, Tatangelo F, Marone P et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 2006 47 : 1241 1248.
45. Wieder HA, Brucher BLDM, Zimmermann F, Becker K, Lordick F, Beer A et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol 2004 22 : 900 908.
46. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol 2007 8 : 797 805.
47. Dooms C, Verbeken E, Stroobants S, Nackaerts K, De Leyn P, Vansteenkiste J. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: A model based on the combination of morphometric- pathologic response in mediastinal nodes and primary tumor response on serial 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography. J Clin Oncol 2008 26 : 1128 1134.
48. Lin M, Shon IH, Wilson R, D'Amours SK, Schlaphoff G, Lin P. Treatment response in liver metastases following 90Y SIR-spheres: an evaluation with PET. Hepatogastroenterology 2007 54 : 910 912.
49. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J et al. 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003 39 : 2012 2020.
50. Scott AM, Gunawardana DH, Kelley B, Stuckey JG, Byrne AJ, Ramshaw JE et al. PET changes management and improves prognostic stratification in patients with recurrent colorectal cancer: results of a multicenter prospective study. J Nucl Med 2008 49 : 1451 1457.
51. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008 33 : 210 222.
52. Yao M, Smith RB, Hoffman HT, Funk GF, Lu M, Menda Y et al. Clinical significance of postradiotherapy [(18)F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer: a long-term outcome report. Int J Radiat Oncol Biol Phys 2009 74 : 9 14.
53. Fulham MJ, Carter J, Baldey A, Hicks RJ, Ramshaw JE, Gibson M. The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project. Gynecol Oncol 2009 112 : 462 468.
54. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006 16 : 109 142.
55. Wiering B, Krabbe PF, Jager GJ, Oyen WJG, Ruers TJM. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 2005 104 : 2658 2670.
56. Pawlik TM, Assumpcao L, Vossen JA, Buijs M, Gleisner AL, Schulick RD et al. Trends in nontherapeutic laparotomy rates in patients undergoing surgical therapy for hepatic colorectal metastases. Ann Surg Oncol 2009 16 : 371 378.
57. Ruers TJM, Wiering B, van der Sijp JRM, Roumen RM, de Jong KP, Comans EFI et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with 18F-FDG PET: a randomized study. J Nucl Med 2009 50 : 1036 1041.
58. Ho Shon IA, Chung DK, Saw RP, Thompson JF. Imaging in cutaneous melanoma. Nucl Med Commun 2008 29 (10 847 876.
59. MacManus M, Nestle U, Rosenzweig KE, Carrio I, Messa C, Belohlavek O et al. Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006-2007. Radiother Oncol 2009 91 : 85 94.
60. Tian J, Yang X, Yu L, Chen P, Xin J, Ma L et al. A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3′-Deoxy-3′-18F-Fluorothymidine and 18F-FDG. J Nucl Med 2008 49 : 186 194.
61. Lee ST, Scott AM. Hypoxia positron emission tomography imaging with 18F-Fluoromisonidazole. Semin Nucl Med 2007 37 : 451 461.